NasdaqCM - Delayed Quote • USD
Compare
At close: June 21 at 4:00 PM EDT
After hours: June 21 at 4:16 PM EDT
Line
Candle
Baseline
Mountain
Bar
Loading Chart for GNPX
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous Close
2.0400 - Open
2.0820 - Bid --
- Ask --
- Day's Range
2.0200 - 2.1400 - 52 Week Range
2.0100 - 42.0000 - Volume
32,118 - Avg. Volume
106,801 - Market Cap (intraday)
4.239M - Beta (5Y Monthly) -0.53
- PE Ratio (TTM)
-- - EPS (TTM)
-18.8100 - Earnings Date Aug 21, 2024 - Aug 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
165.00
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
26
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
More about Genprex, Inc.
Recent News: GNPX
All SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
Performance Overview: GNPX
Trailing total returns as of 6/21/2024, which may include dividends or other distributions. Benchmark is
YTD Return
GNPX
78.04%
S&P 500
14.57%
1-Year Return
GNPX
93.69%
S&P 500
24.52%
3-Year Return
GNPX
98.51%
S&P 500
31.16%
5-Year Return
GNPX
96.42%
S&P 500
84.98%
Compare To: GNPX
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
2.0200
-0.98%
Mkt Cap 4.239M
Industry Biotechnology
2.4500
+0.41%
Mkt Cap 109.606M
Industry Biotechnology
1.2500
-7.41%
Mkt Cap 37.272M
Industry Biotechnology
6.42
-1.83%
Mkt Cap 176.808M
Industry Biotechnology
1.4000
-5.41%
Mkt Cap 2.791M
Industry Biotechnology
4.5800
+1.33%
Mkt Cap 187.609M
Industry Biotechnology
0.4345
+3.04%
Mkt Cap 43.925M
Industry Biotechnology
8.50
+8.01%
Mkt Cap 522.028M
Industry Biotechnology
0.1400
-0.71%
Mkt Cap 148.17M
Industry Biotechnology
1.9000
-6.86%
Mkt Cap 76.111M
Industry Biotechnology
5.40
0.00%
Mkt Cap 15.209M
Industry Biotechnology
Statistics: GNPX
Valuation Measures
As of 6/21/2024
Market Cap
4.24M
Enterprise Value
-3.98M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-96.86%
Return on Equity (ttm)
-202.83%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-27.63M
Diluted EPS (ttm)
-18.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
8.22M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-13.02M
Research Analysis: GNPX
Company Insights: GNPX
Research Reports: GNPX
People Also Watch
DARE Daré Bioscience, Inc.
0.4345
+3.04%
CODX Co-Diagnostics, Inc.
1.4700
+1.38%
COCP Cocrystal Pharma, Inc.
2.6600
+4.31%
AIM AIM ImmunoTech Inc.
0.4104
+4.29%
AYTU Aytu BioPharma, Inc.
2.9100
+4.68%
OPGN OpGen, Inc.
2.4100
+2.12%
VTVT vTv Therapeutics Inc.
18.83
-1.21%
AGRX Agile Therapeutics, Inc.
0.3170
0.00%
NNVC NanoViricides, Inc.
1.8200
-10.34%
CTXR Citius Pharmaceuticals, Inc.
0.6090
-4.92%
PIXY ShiftPixy, Inc.
1.8100
-7.65%
CAPR Capricor Therapeutics, Inc.
4.7000
-1.26%
CLSD Clearside Biomedical, Inc.
1.0800
-6.09%
HOTH Hoth Therapeutics, Inc.
0.9240
-0.66%
BSGM BioSig Technologies, Inc.
0.3580
+3.77%
VBIV VBI Vaccines Inc.
0.5980
+2.01%